 BiondVax Pharmaceuticals Ltd. Nasdaq: BVXV today announced that all participants in the placebo-controlled, blinded, pivotal, clinical efficacy, Phase 3 trial of BiondVaxs M001 universal influenza vaccine candidate have now completed their site visits. In total, over 12,400 volunteers aged 50 with half aged 65 were enrolled in the trial over the past two flu seasons in 83 sites across seven European countries. The purpose of the study is to assess M-001s ability as a standalone non-adjuvanted vaccine to provide clinical protection from circulating influenza strains as measured by reduction of influenza illness rate as a primary endpoint and severity as a secondary endpoint, as well as to assess M-001s safety. 